Arix Bioscience to present at H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018
LONDON, 5 April 2018: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience") a global healthcare and life science company supporting medical innovation, announces that Joe Anderson, CEO, will present at the H.C. Wainwright & Co. Global Life Sciences Conferenceon 10 April 2018, at 11.30 CEST at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com
This information is provided by RNS
The company news service from the London Stock Exchange
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease.
Through the deal Arix receives a 10% stake in the company while also...